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Tissue culture studies of possible uremic neurotoxins: Myoinositol.
Organotypic cultures of dorsal root ganglion cells revealed neu-
ronal toxicity when exposed to myoinositol at doses of 1090 to
IO9MM (500 to 50tg/m1). The ultrastructural changes consisted of
membranous cytoplasmic bodies at high concentrations and dense
bodies at lower concentrations. There were no changes at 0 to 22MM
(0 to l0ttg/ml). This range of neurotoxicity parallels the levels of
myoinositol found in the serum of uremic patients. Myelin loss
occurred in a pattern suggesting "secondary demyelination," sim-
ilar to the pattern seen in uremic neuropathy. The relevance as a
possible model for uremic neuropathy is discussed.
Etudes sur des cultures tissulaires de toxines urémiques poten-
tielles: Myoinositol. Des cultures organotypiques de cellules gangli-
onnaires de Ia racine dorsale permettent de mettre une toxicité en
evidence lors de l'exposition au myoinositol a des concentrations
de 1090 a 109MM (500 a 50Mg/mI). Les modifications ultrastructur-
ales consistent en des inclusions cytoplasmiques membraneuses
aux fortes concentrations et des inclusions denses aux faibles con-
centrations. Aucune modification n'a été observée aux concentra-
tions entre 0 et 22MM (0 a I0 Mg/mI). Ce niveau de neurotoxicité est
semblable aux concentrations de myoinositol trouvées dans le sé-
rum des malades urémiques. La perte de myeline se produit scIon
des modalités qui suggèrent une "démyélinisation secondaire"
semblables a celles observées dans Ia neuropathie urémique.
L'intérêt de cette preparation en tant que modèle de neuropathie
urémique est discuté.
Although neuropathy is a common complication
of uremia, the responsible neurotoxin or toxins have
not been established. Possible candidates include
methyl guanidine [1—5] "middle molecular weight"
molecules [6—9], and urea cycle amino acids [10—12].
The sugar alcohol, myoinositol, has been suggested
because it is elevated in the blood of uremic patients
[13, 141 in spite of its low mol wt and high water
solubility. Furthermore, rats fed with myoinositol
demonstrate a slowing of sciatic nerve conduction
velocity which is reversible on cessation of myoinosi-
to! ingestion [14, 15].
Organotypic cultures of mammalian nerve tissues
have served as bonafide models for the evaluations of
a number of putative neurotoxins [16]. To further test
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for possible myoinositol neurotoxicity, it was in-
corporated into the nutrient medium of cultured
mouse spinal cord-dorsal root ganglion complexes.
The morphologic responses of the exposed tissues
were examined by light and electron microscopy. The
results of these observations are the subject of this
report.
Methods
Organotypic cultures were prepared under sterile
conditions from 13 to 14 day-old Swiss CD (Charles
River) mouse embryos. Explants consisted of cord
sections 0.5 to I .0 mm thick with dorsal root ganglia
attached and meningeal coverings preserved. These
were maintained on collagen-coated coverslips within
Maximow slide assemblies in the lying drop position
at 34 to 35°C. Each culture was washed twice a week
in Simms' Balanced Salt Solution and fed a fresh
drop of nutrient medium. The latter consisted of 10%
chick embryo extract, 33% human placental cord se-
rum, 53% Eagle's Minimum Essential Medium with
glutamine, 600 mg of glucose per 100 ml, and 1.2
tg/ml achromycin with ascorbic acid [17].
Some explants in both the test and the control
groups had nerve growth factor incorporated into
their nutrient medium (5 to 25 U/mI) during their
first 4 to 5 days in vitro. Cultures were maintained for
II to 40 days in vitro before exposure to the test
solutions. Neurons could be evaluated even in the
youngest cultures. Central myelin matured after ap-
proximately 18 days in vitro, and peripheral myelin
after approximately 28 days in vitro.
A total of 62 cultures were exposed to added
myoinositol, ranging from 22tM (l0zg/ml) to
l090tM (500g/ml). Controls consisted of 36 cultures
maintained in parallel, but with no myoinositol
added. There was no significant difference between
the test solutions and the control solutions in their
osmolality. The nutrient containing l090tM
(500tg/ml) of myoinositol had an osmolality of 291
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mOsm/liter as compared to 324 mOsm/liter in the
control solution.
All cultures were coded and observed periodically
in the living, unstained state under light microscopy.
The dorsal root ganglion cells and, in mature cul-
tures, the central and peripheral myelin were eval-
uated at magnifications up to 600 diameters.
For ultrastructural examination, cultures were
fixed in 2.5% glutaraldehyde in Millonig's buffer, fol-
lowed by 1% osmium tetroxide, then dehydration,
propylene oxide treatment, and finally Epon embed-
ding. Thin sections (prepared on an LKB microtome)
were stained with lead citrate and uranyl acetate.
Examination was on an electron microscope (Phillips
200).
Results
A total of 15 cultures were exposed to l090tM
(500g/ml) of myoinositol. No distinction could be
made between these and control cultures in the state
of the central myelin. Under light microscopic obser-
vation, granulation in the dorsal root ganglion cells
was evident by three days of exposure and was severe
after six days (Figs. 1, 7). No such granulation was
seen in the cultures exposed to nutrient alone, al-
though some were examined by light microscopy for
as long as 50 days of exposure.
With the electron microscope, the granules were
seen to be membranous cytoplasmic bodies with an
interlaminar periodicity of 60 A (Figs. 2 and 3). In
control cultures, membranous cytoplasmic bodies
were occasionally seen, but usually just one or two in
isolated cells. In contrast, the cytoplasm of neurons
exposed to myoinositol was virtually filled with these
inclusions (Figs. 1, 2). They were also present but to a
lesser degree in the cytoplasm of Schwann cells (Fig.
4), satellite cells, macrophages, and connective tissue
in these cultures.
A total of 13 cultures were exposed to 436tM
(200tg/ml) and 6 to 2I8M (l00g/ml) of myoinosi-
tol. Granulation was apparent in the dorsal root gan-
glion cells under light microscopic observation after
four to seven days of exposure to the higher concen-
tration and after eight days of exposure to the lower
concentration. At the higher concentration only, ab-
normalities were also present in Schwann cells and
satellite cells. Ultrastructurally, the granules were
found to be cytoplasmic dense bodies (Figs. 5, 6). Of
note, some inclusions revealed transitional features
with characteristics resembling membranous cy-
toplasmic bodies too (Fig. 5).
On prolonged exposure of explants to l090tM
(500tg/ml) and 436tM (200ig/ml) of myoinositol,
demyelination was observed under the light micro-
scope after 24 and 50 days of exposure, respectively.
Myelin degeneration occurred along substantial
Fig. 1. Cross section of dorsal root gang/ion exposed to 1O9OM (500 /2g/ml) of myoinositolfor ten
days (toluidine blue, X250).
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Fig. 2. Cytoplasmic inclusions seen in Fig. 1 (EM, X6100). Fig. 3. Higher power view of these inclusions revealing small area of
periodicity (EM, X150.000).
Fig. 4. Inclusions in Schwann cell cytoplasm after exposure to Fig. 5. Cytoplasmic dense bodies in dorsal root ganglion cells after
/O9O,M (5OOzg/ml) of myoinositol for ten days (EM, X23,000). nine days of exposure to 436tM (2OOg/ml) of myoinositol. Small
area with rudimentary lamellation is seen. EM, X41,000.
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Fig. 6. High power view of cytoplasmic dense bodies (seven days of
exposure to 436GM (2OOzg/m1) of myoinositol) (EM, X97,000).
lengths of isolated nerve fibers (Fig. 7). Adjacent
fibers were often spared. Myelin loss confined to an
isolated segment was a less frequent finding, occur-
ring no more frequently than in control cultures.
At a l09sM (50tg/m1) concentration of myoinosi-
to!, nine cultures became granular after eight to nine
days of exposure, containing neuronal dense bodies
ultrastructurally. Repeat testing of two additional
cultures failed to reveal any of these changes after 11
days of exposure. Seventeen cultures exposed to
myoinositol at a concentration of 221LM (1Ozg/ml) for
9 to 20 days did not show any granular changes under
light microscopic observation. Those examined ultra-
structurally were indistinguishable from the control
cultures.
Discussion
On exposure of dorsal root ganglion cells to myoi-
nositol, cytoplasmic abnormalities formed in all neu-
rons within several days. These findings occurred at
concentrations ranging from 218tM (l00tg/ml)
through l090tM (500tg/ml) with inconstant changes
at l09tM (50g/ml). No significant osmolality
changes were noted. In uremic patients, serum myo-
inositol has been found in concentrations of 942
180tM (SD) [13] in one study and of 390 7l.ltM
(sEM) in another with a range of 138 to 1 l68tM [14].
Control patients had levels of 63 24iM (SD) [13]
and 24 l.ltM (sEM) [14], respectively. Similarly,
cultures exposed to 22tM (l0sg/ml) were identical to
control cultures. Thus, the in vitro neurotoxicity of
myoinositol occurred at levels analogous to the se-
rum concentration found in uremic patients.
The occurrence of membranous cytoplasmic bod-
ies and dense bodies has been reported in many or-
gans after exposure to many substances [18—26] and
in several individual pathological entities [27, 28].
Because of this, the changes observed in in vitro
myoinositol toxicity have no significant specificity.
The cultures reveal obvious neurotoxicity. In the
cultures exposed to l090sM of myoinositol, the tox-
icity extended to all cell types, including Schwann
cells (Fig. 4). In spite of some primary Schwann cell
changes under electron microscopy, the light micro-
scopic picture of myelin changes did not consist of
segmental demyelination. In neuropathic processes
primarily involving the myelin sheath, single neurons
may reveal isolated segments between nodes of Ran-
vier devoid of myelin or with abnormal myelin. In-
stead, the myelin disintegration which occurred con-
sisted of linear rows of myelin ovoids and myelin
balls in individual fibers with adjacent fibers spared
(Fig. 7). This pattern usually occurs in neuropathic
Fig. 7. Dorsal root ganglion cells showing severe neuronal granula-
tion and linear rows of myelin ovoids (arrows) after prolonged ex-
posure (24 days) to IO9OM (5OOg/ml) of myoinositol (living cul-
ture, X400).
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processes primarily involving the axons. The pro-
longed delay before the demyelination was observed
is further evidence of an axonal neuropathy because a
long period of neuronal degeneration would have to
precede the demyelination.
In chronic uremic neuropathy, the neuropathic
process is considered to be an axonal "dying-back"
process due to primary nerve cell pathology [29—34].
In some reports, segmental demyelination was ob-
served, which led to the conclusion that the neu-
ropathy might be due to primary Schwann cell tox-
icity [35—38]. (Note, however, that segmental
demyelination might be due to primary axonopathy
[33, 39] and may not imply Schwann cell pathology.)
In any case, the in vitro myoinositol findings reflect
pathologic changes analogous to those reported in
chronic uremic neuropathy—namely primary axonal
neuropathy with secondary demyelination.
The exact biochemical effect of myoinositol caus-
ing this toxicity is still unknown. Myoinositol is a
component of central and peripheral myelin. in the
form of di- and tri-phosphoinositide. Since these con-
tain phosphates with high turnover rates [40], they
are a part of the rapidly-metabolized fraction of the
nervous system. Some of its known pharmacologic
effects include inhibition or activitation of a- and f-
galactosidase enzymatic activity in vitro [41, 42]. In
addition, myoinositol or scylloinositol added to the
antigen decrease experimental allergic encephalito-
genic response in guinea pigs [43]. On the basis of our
present limited information, one can only speculate
about the biochemical mechanism of myoinositol
toxicity.
It is important to emphasize that we are dealing
with an in vitro model whose in vivo relevance is
unproven. Of significance, myoinositol exhibited neu-
rotoxicity in vitro at the same concentrations as
found in uremic sera. Furthermore, the changes sug-
gest primary neurotoxicity with secondary demyeli-
nation—analogous to chronic uremic neuropathic
changes. Because of these facts, myoinositol, which
has in vitro neurotoxicity, is a strong candidate as an
in vivo neurotoxin of uremia.
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